

William R Gwin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/628860/publications.pdf>

Version: 2024-02-01

15
papers

489
citations

933447

10
h-index

1199594

12
g-index

16
all docs

16
docs citations

16
times ranked

756
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27
2	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. Cancer Research, 2022, 82, PD8-01-PD8-01.	0.9	4
3	Vaccine Therapies for Cancer: Then and Now. Targeted Oncology, 2021, 16, 121-152.	3.6	90
4	Long-term survival of patients with stage III colon cancer treated with VPR-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
5	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. Communications Biology, 2020, 3, 226.	4.4	18
6	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clinical Cancer Research, 2019, 25, 2725-2736.	7.0	50
7	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. Cancer Chemotherapy and Pharmacology, 2018, 81, 365-372.	2.3	8
8	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research, 2018, 20, 90.	5.0	14
9	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. Oncolmunology, 2017, 6, e1264563.	4.6	23
10	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. Oncolmunology, 2017, 6, e1315495.	4.6	17
11	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clinical Cancer Research, 2017, 23, 5066-5073.	7.0	62
12	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research, 2017, 23, 7531-7542.	7.0	15
13	Use of the TLR2 ligand polysaccharide krestin to maximize conventional cancer therapy. Expert Review of Quality of Life in Cancer Care, 2017, 2, 133-135.	0.6	0
14	Pertuzumab Protects the Achilles' Heel of Trastuzumabâ€”Emtansine. Clinical Cancer Research, 2014, 20, 278-280.	7.0	13
15	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Research, 2013, 15, R85.	5.0	120